Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer's disease

[1]  Hyun-jeong Liew,et al.  Soluble Neuregulin-1 as a Diagnostic Biomarker for AlzheimerâÂÂs Disease , 2016 .

[2]  Y. Suh,et al.  Soluble Neuregulin-1 from Microglia Enhances Amyloid Beta-induced Neuronal Death. , 2016, CNS & neurological disorders drug targets.

[3]  Kyu-Hee Lee,et al.  Bidirectional Signaling of Neuregulin-2 Mediates Formation of GABAergic Synapses and Maturation of Glutamatergic Synapses in Newborn Granule Cells of Postnatal Hippocampus , 2015, The Journal of Neuroscience.

[4]  Martin Rossor,et al.  Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. , 2015, Brain : a journal of neurology.

[5]  Tao Wang,et al.  The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease , 2014, International journal of geriatric psychiatry.

[6]  Ya-Fang Chen,et al.  Plasma tau as a window to the brain—negative associations with brain volume and memory function in mild cognitive impairment and early alzheimer's disease , 2014, Human brain mapping.

[7]  Deming Zhao,et al.  Protein-Based Biomarkers in Cerebrospinal Fluid and Blood for Alzheimer’s Disease , 2014, Journal of Molecular Neuroscience.

[8]  Zhang Wenmin,et al.  Neuroprotective effects of neuregulin-1 ß on oligodendrocyte type 2 astrocyte progenitors following oxygen and glucose deprivation. , 2014, Pediatric neurology.

[9]  J. Morris,et al.  Diurnal Patterns of Soluble Amyloid Precursor Protein Metabolites in the Human Central Nervous System , 2014, PloS one.

[10]  W. Nacken,et al.  S100A9 Knockout Decreases the Memory Impairment and Neuropathology in Crossbreed Mice of Tg2576 and S100A9 Knockout Mice Model , 2014, PloS one.

[11]  B. Popescu,et al.  Functional and molecular characterization of the effect of amyloid-β42 on an in vitro epithelial barrier model. , 2013, Journal of Alzheimer's disease : JAD.

[12]  Magda Tsolaki,et al.  Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. , 2013, Journal of Alzheimer's disease : JAD.

[13]  S. Shankar,et al.  The role of pro-inflammatory S100A9 in Alzheimer’s disease amyloid-neuroinflammatory cascade , 2013, Acta Neuropathologica.

[14]  B. Ray,et al.  Abnormal cerebrospinal fluid (CSF) dynamics in Alzheimer's disease and normal pressure hydrocephalus: CSF‐amyloid β precursor protein metabolites as possible biomarkers , 2013, European journal of neurology.

[15]  A. Simon,et al.  Characterization of plasma β‐secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease , 2012, Journal of neuroscience research.

[16]  P. Yip,et al.  New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer's disease. , 2012, Current Alzheimer research.

[17]  Paul Edison,et al.  Drug repositioning for Alzheimer's disease , 2012, Nature Reviews Drug Discovery.

[18]  Y. Ishikawa,et al.  Processing of Neuregulin-1 by Neuropsin Regulates GABAergic Neuron to Control Neural Plasticity of the Mouse Hippocampus , 2012, The Journal of Neuroscience.

[19]  Steven Hou,et al.  Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. , 2012, Brain : a journal of neurology.

[20]  J. Gilthorpe,et al.  MRP14 (S100A9) Protein Interacts with Alzheimer Beta-Amyloid Peptide and Induces Its Fibrillization , 2012, PloS one.

[21]  Mary Johnson.  Loading Controls for Western Blots , 2012 .

[22]  Y. Suh,et al.  The Role of S100a9 in the Pathogenesis of Alzheimer’s Disease: The Therapeutic Effects of S100a9 Knockdown or Knockout , 2012, Neurodegenerative Diseases.

[23]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[24]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[25]  E. Lambe,et al.  Schizophrenia susceptibility pathway neuregulin 1–ErbB4 suppresses Src upregulation of NMDA receptors , 2011, Nature Medicine.

[26]  Anne Corbett,et al.  Alzheimer's disease , 2011, The Lancet.

[27]  S. Nakai,et al.  Reduction of Alzheimer’s Disease Amyloid-β in Plasma by Hemodialysis and Its Relation to Cognitive Functions , 2011, Blood Purification.

[28]  F. Jessen,et al.  Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing , 2010, Experimental Neurology.

[29]  Yukunori Korogi,et al.  The efficacy of a voxel-based morphometry on the analysis of imaging in schizophrenia, temporal lobe epilepsy, and Alzheimer's disease/mild cognitive impairment: a review , 2010, Neuroradiology.

[30]  H. Yamasue,et al.  Voxel-based analysis of the diffusion tensor , 2010, Neuroradiology.

[31]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[32]  Y. Suh,et al.  S100a9 Knockdown Decreases the Memory Impairment and the Neuropathology in Tg2576 Mice, AD Animal Model , 2010, PloS one.

[33]  Xin-Hong Zhu,et al.  Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons , 2009, Proceedings of the National Academy of Sciences.

[34]  N. Schuff,et al.  Influence of selecting EPI readout-encoding bandwidths on arterial spin labeling perfusion MRI , 2009, Magnetic Resonance Materials in Physics, Biology and Medicine.

[35]  A. Buonanno,et al.  Neuregulin links dopaminergic and glutamatergic neurotransmission to control hippocampal synaptic plasticity , 2009, Communicative & integrative biology.

[36]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease , 2009, Acta Neuropathologica.

[37]  J. Loeb,et al.  Differential distribution of neuregulin in human brain and spinal fluid , 2009, Brain Research.

[38]  J. Kapfhammer,et al.  Neuregulin Signaling Is Dispensable for NMDA- and GABAA-Receptor Expression in the Cerebellum In Vivo , 2009, The Journal of Neuroscience.

[39]  M. Bumbasirevic,et al.  [Cerebrospinal fluid amyloid beta and tau protein: biomarkers for Alzheimer's disease]. , 2008, Vojnosanitetski pregled.

[40]  L. Mei,et al.  Neuregulin 1 in neural development, synaptic plasticity and schizophrenia , 2008, Nature Reviews Neuroscience.

[41]  Jos H Beijnen,et al.  Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. , 2008, Current clinical pharmacology.

[42]  B. Dubois,et al.  Amnestic syndrome of the medial temporal type identifies prodromal AD , 2007, Neurology.

[43]  Y. Suh,et al.  A novel compound, maltolyl p‐coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models , 2007, Journal of neuroscience research.

[44]  H. Hinterhuber,et al.  Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. , 2007, Drugs of today.

[45]  P. Angel,et al.  S100A8 and S100A9 in inflammation and cancer. , 2006, Biochemical pharmacology.

[46]  G. Halliday,et al.  Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease , 2006, Neurobiology of Aging.

[47]  G. Corfas,et al.  Presenilin-Dependent ErbB4 Nuclear Signaling Regulates the Timing of Astrogenesis in the Developing Brain , 2006, Cell.

[48]  Karin E. Borgmann-Winter,et al.  Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.

[49]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[50]  T. Kinoshita,et al.  [Evaluation of three-dimensional fast spoiled gradient recalled acquisition in the steady state (FSPGR) using ultra magnetic field 3-Tesla MRI for optimal pulse sequences of T1-weighted imaging]. , 2006, Nihon Hoshasen Gijutsu Gakkai zasshi.

[51]  S. Burden,et al.  Neuromuscular Synapse Formation in Mice Lacking Motor Neuron- and Skeletal Muscle-Derived Neuregulin-1 , 2006, The Journal of Neuroscience.

[52]  A. Baldwin,et al.  S100-mediated signal transduction in the nervous system and neurological diseases. , 2005, Cellular and molecular biology.

[53]  Zhen Yan,et al.  Regulation of NMDA Receptors by Neuregulin Signaling in Prefrontal Cortex , 2005, The Journal of Neuroscience.

[54]  F. Coppedè,et al.  Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients , 2005, Neurobiology of Aging.

[55]  Rüdiger Klein,et al.  The neuregulin receptor, ErbB4, is not required for normal development and adult maintenance of the substantia nigra pars compacta , 2004, Journal of neurochemistry.

[56]  A. Fasolo,et al.  ErbB4 Expression in Neural Progenitor Cells (ST14A) Is Necessary to Mediate Neuregulin-1β1-induced Migration* , 2004, Journal of Biological Chemistry.

[57]  J. Loeb,et al.  Synergistic effects of neuregulin and agrin on muscle acetylcholine receptor expression , 2004, Molecular and Cellular Neuroscience.

[58]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.

[59]  Douglas L Falls,et al.  Neuregulins: functions, forms, and signaling strategies. , 2003, Experimental cell research.

[60]  Fu-Chin Liu,et al.  Neural development of the neuregulin receptor ErbB4 in the cerebral cortex and the hippocampus: preferential expression by interneurons tangentially migrating from the ganglionic eminences. , 2003, Cerebral cortex.

[61]  S. Carroll,et al.  Neuregulin–1 and ErbB4 Immunoreactivity Is Associated with Neuritic Plaques in Alzheimer Disease Brain and in a Transgenic Model of Alzheimer Disease , 2003, Journal of neuropathology and experimental neurology.

[62]  D. Y. Lee,et al.  The Prevalence of Dementia in Older People in an Urban Population of Korea: The Seoul Study , 2002, Journal of the American Geriatrics Society.

[63]  G. Lenzi,et al.  Amyloid precursor protein in platelets , 2001, Neurology.

[64]  J. Loeb,et al.  Neuregulin-heparan-sulfate proteoglycan interactions produce sustained erbB receptor activation required for the induction of acetylcholine receptors in muscle. , 2001, The Journal of biological chemistry.

[65]  F. Jessen,et al.  Plasma 24S‐hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease , 2000, Neuroreport.

[66]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[67]  Alan C. Evans,et al.  Volumetry of hippocampus and amygdala with high-resolution MRI and three-dimensional analysis software: minimizing the discrepancies between laboratories. , 2000, Cerebral cortex.

[68]  M. Rafii,et al.  Agrin in Alzheimer's Disease: Altered Solubility and Abnormal Distribution within Microvasculature and Brain Parenchyma , 1999 .

[69]  S. Izumo,et al.  Activation of macrophages/microglia with the calcium-binding proteins MRP14 and MRP8 is related to the lesional activities in the spinal cord of HTLV-I associated myelopathy , 1999, Journal of Neurology.

[70]  G. Fischbach,et al.  Expression patterns of transmembrane and released forms of neuregulin during spinal cord and neuromuscular synapse development. , 1999, Development.

[71]  H. Schluesener,et al.  Expression of the S‐100 proteins MRP‐8 and ‐14 in ischemic brain lesions , 1997, Glia.

[72]  L. Eriksson,et al.  Structure of heparan sulphate from human brain, with special regard to Alzheimer's disease. , 1995, The Biochemical journal.

[73]  W. Nitz,et al.  MP RAGE: a three-dimensional, T1-weighted, gradient-echo sequence--initial experience in the brain. , 1992, Radiology.

[74]  P. Mölsä,et al.  Survival and cause of death in Alzheimer's disease and multi‐infarct dementia , 1986, Acta neurologica Scandinavica.

[75]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[76]  M. Roth,et al.  The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.

[77]  D. Alkon,et al.  Peripheral biomarkers of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[78]  F. Jessen,et al.  Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[79]  H. Vanderstichele,et al.  Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics. , 2012, Journal of Alzheimer's disease : JAD.

[80]  A. Slachevsky,et al.  Human platelets tau: a potential peripheral marker for Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[81]  S. Engelborghs,et al.  Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients. , 2010, Journal of Alzheimer's disease : JAD.

[82]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[83]  S. Jo,et al.  Identification of peripheral inflammatory markers between normal control and Alzheimer's disease , 2011, BMC neurology.